MiR-130b may enhance ENaC and involve in the BMSCs-based therapy of ALI by targeting PTEN and activating PI3K/AKT pathway in LPS-treated AT2 cells, which represents a promising direction for therapeutic strategy of ALI. The gene discussed is AKT1; the disease is acute respiratory distress syndrome.